Crexendo, Inc. CXDO 深 滬
已收盤 02-06 16:00:00 美东时间
6.53
+0.285
+4.56%
華盛通- 最 高6.6699
- 今 開6.34
- 成交量 9.96万股
- 最 低 6.34
- 昨 收 6.245
- 總市值 2.01亿
- 52周最高 7.80
- 市盈率 靜 116.82
- 換手率 0.32%
- 52周最低 3.75
- 委 比 50.54%
- 總股本 3073.10万
- 歷史最高 12.756
- 量 比 0.47
- 振 幅 5.28%
- 歷史最低 1.2399
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Crexendo Inc. to Hold Fourth Quarter and Year End Financial Results Conference Call
Crexendo Inc. to Hold Fourth Quarter and Year End Financial Results Conference Call Crexendo, Inc. (NASDAQ:CXDO) will announce its fourth quarter and year end 2025 financial results on March 3, 2026, at 4:30 p.m. ET. A conference call will be held the same day for investors and analysts, featuring J
02-03 22:01
Crexendo and Altigen Technologies Enter Cloud Communications Licensing Agreement
Crexendo and Altigen Technologies Enter Cloud Communications Licensing Agreement Crexendo Inc., a leading provider of cloud communication platform software and unified communications as a service (UCaaS), has announced a licensing and collaboration agreement with Altigen Technologies. Under the arra
01-29 22:00
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
2025-11-06 09:55
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
Needham Maintains Buy on Crexendo, Raises Price Target to $9
Needham analyst Joshua Reilly maintains Crexendo (NASDAQ:CXDO) with a Buy and raises the price target from $8 to $9.
2025-10-30 19:24
Crexendo Announces Full Integration Support For Six Additional Mitel 6900 Series IP Phones On NetSapiens Platform
Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including
2025-08-20 21:03
美股大行评级 | Rivian遭多家大行下调目标价；巴克莱上调超微公司目标价从130美元升至200美元
今日重点评级关注：韦德布什：维持Gossamer Bio"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持EyePoint Pharmaceuticals"买入"评级，目标价从22美元升至23美元
2025-08-07 09:46
D. Boral Capital Maintains Buy on Crexendo, Raises Price Target to $11
D. Boral Capital analyst Jesse Sobelson maintains Crexendo (NASDAQ:CXDO) with a Buy and raises the price target from $10 to $11.
2025-08-06 21:13
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
2025-07-02 09:54
Crexendo's Open Strategy Pays Off, Analyst Praises 'Disruptive Pricing Model'
Crexendo's pre-packaged features have the "right balance of configuration" for both retail and wholesale customer wins, analysts say.
2025-07-01 22:31
